Post-HAART outcomes in pediatric populations: Comparison of resource-limited and developed countries

Pediatrics

Volumn 127, Issue 2, 2011, Pages

  Peacock Villada, Elizabeth ^a   Richardson, Barbra A ^b   John Stewart, Grace C ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HAART; HIV AIDS; Mortality; Pediatric; Resource limited

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; DEVELOPED COUNTRY; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CLINICAL TRIALS AS TOPIC; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 79551536835     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-2701     Document Type: Review

References (215)

1. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-733
2. Gortmaker SL, Hughes M, Cervia J, et al; Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345(21):1522-1528
3. Newell M, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364(9441):1236-1243
4. Spira R, Lepage P, Msellati P, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics. 1999;104(5). Available at: www.pediatrics.org/cgi/content/full/104/5/e56
5. Joint United Nations Programme on HIV/AIDS. 2008 report on the global AIDS epidemic. Available at: www.unaids.org/en/KnowledgeCentre/HIVData/ GlobalReport/2008/2008-Global-report.asp. Accessed December 23, 2009
6. Boerma J, Stanecki K, Newell M, et al. Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ. 2006;84(2):145-150
7. American Academy of Pediatrics, Committee on Pediatric AIDS, Section on International Child Health; Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. Pediatrics. 2007;119(4):838-845
8. Gill C, Hamer D, Simon J, Thea D, Sabin L. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19(12):1243-1249
9. Church JA, Hughes M, Chen J, et al; Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2004;23(8):713-718
10. O'Brien D, Sauvageot D, Zachariah R, Humblet P. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20(15):1955-1960 (Pubitemid 44427613)
11. Krogstad P, Lee S, Johnson G, et al; Pediatric AIDS Clinical Trials Group 377 Study Team. Nucleoside-analogue reversetranscriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34(7):991-1001
12. George E, Noël F, Bois G, et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis. 2007;195(10):1411-1418 (Pubitemid 46717458)
13. Myung P, Pugatch D, Brady M, et al. Directly observed highly active antiretroviral therapy for HIV-infected children in Cambodia. Am J Public Health. 2007;97(6):974-977
14. Sutcliffe C, van Dijk J, Bolton C, Persaud D, Moss W. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8(8):477-489
15. WHO and UNAIDS release update that focuses on HIV prevention. IAVI Rep. 2005;9(5):20
16. Antiretroviral therapy for children in the routine setting in Malawi. Trans R Soc Trop Med Hyg. 2007;101(5):511-516
17. Ciaranello A, Chang Y, Margulis A, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009;49(12):1915-1927
18. United Nations Statistics Division. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. Available at: http://unstats.un.org/unsd/methods/m49/m49regin.htm. Accessed April 30, 2010
19. Hien H, Nacro B, Zouré E, et al. Once-a-day paediatric HAART with DDI+3TC+EFV in West Africa:24monthvirologicalandimmunological outcomes [abstract MOPEB031]. ANRS12103/12167 trial. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa. Available at: www.ias2009.org/abstract.aspx?elementId=200722693. Accessed December 15, 2010
20. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1 infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18(14):1905-1913
21. Rouet F, Fassinou P, Inwoley A, et al; ANRS 1244/1278 Programme Enfants Yopougon. Long-term survival and immunovirological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20(18):2315-2319
22. Nyandiko W, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and nonorphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defic Syndr. 2006;43(4):418-425
23. Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics. 2007;120(4). Available at: www.pediatrics.org/cgi/content/full/120/4/e856
24. Van Winghem J, Telfer B, Reid T, et al. Implementation of a comprehensive program including psycho-social and treatment literacy activities to improve adherence to HIV care and treatment for a pediatric population in Kenya. BMC Pediatr. 2008;8:52
25. Wamalwa D, Farquhar C, Obimbo E, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45(3):311-317
26. Reddi A, Leeper S, Grobler A, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13
27. Leyenaar J, Novosad P, Ferrer K, et al. Early clinical outcomes in children enrolled in human immunodeficiency virus infection care and treatment in Lesotho. Pediatr Infect Dis J. 2010;29(4):340-345
28. Cohen R, Lynch S, Bygrave H, et al. Nursedriven, community-supported HIV/AIDS care and treatment: 2 year antiretroviral treatment outcomes from a primary care level programme in rural Lesotho [abstract MOAD102]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa. Available at: www.ias2009.org/ abstract.aspx?elementId=200722512. Accessed December 15, 2010
29. Bong C, Yu J, Chiang H, et al. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi. AIDS. 2007;21(13):1805-1810 (Pubitemid 47237569)
30. Weigel R, Keiser O, Gumulira J, et al. Growth response to ART in HIV-infected children from Lilongwe, Malawi [paper 848]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. Available at: www.retroconference.org/2010/Abstracts/37992. htm. Accessed December 15, 2010
31. Marazzi M, Germano P, Liotta G, Buonomo E, Guidotti G, Palombi L. Pediatric highly active antiretroviral therapy in Mozambique: an integrated model of care [in Italian]. Minerva Pediatr. 2006;58(5):483-490
32. Vaz P, Santos P, Augusto O, Macassa E, Blanche S, Andersson S. The impact of antiretroviral treatment on growth of HIV-1 infected children in Maputo, Mozambique [abstract WEPEB197]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa. Available at: www.ias2009.org/abstract.aspx?elementId=200722321. Accessed December 15, 2010
33. van Griensven J, De Naeyer L, Uwera J, Asiimwe A, Gazille C, Reid T. Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care. BMC Pediatr. 2008;8:39
34. Diack MBaye A, Signaté Sy H, Diagne Guèye NR, et al. Epidemiological and clinical aspects of paediatric HIV infections in Albert- Royer Paediatric Hospital (Dakar, Senegal) [in French]. Arch Pediatr. 2005;12(4):404-409
35. Barth R, van der Meer J, Hoepelman A, et al. Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis. 2008;27(10):977-984
36. Eley B. Addressing the paediatric HIV epidemic: a perspective from the Western Cape region of South Africa. Trans R Soc Trop Med Hyg. 2006;100(1):19-23
37. Jaspan H, Berrisford A, Boulle A. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J. 2008;27(11):993-998
38. Jooste J, Van Zyl A, Baker A, Crawford W, Jassen A. Antiretroviral treatment in the Northern Cape. S Afr Med J. 2005;95(11):812
39. Smit EJ, Rabie H, Prozesky H, Cotton M. Pediatric outcome 42 months after highly active antiretroviral therapy availability in the public sector: the Tygerberg Children's Hospital experience [abstract MOPEB079]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa. Available at: www.ias2009.org/abstract. aspx?elementId=200721774. Accessed December 15, 2010
40. Blè C, Floridia M, Muhale C, et al. Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in Tanzania. Acta Paediatr. 2007;96(7):1090-1094 (Pubitemid 46934464)
41. Kamya MR, Mayanja-Kizza H, Kambugu A, et al; Academic Alliance for AIDS Care and Prevention in Africa. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46(2):187-193
42. Bolton-Moore C, Mubiana-Mbewe M, Cantrell R, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298(16):1888-1899
43. Gupta RK, Ford D, Kabamba D, et al. Two year virological outcomes in HIV-1 infected Zambian children using adult Triomune (fixed dose combination d4T, 3TC and NVP) [abstract MOPEB056]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa. Available at: www.ias2009.org/abstract.aspx?elementId= 200722143. Accessed December 15, 2010
44. Walker AS, Mulenga V, Ford D, et al; CHAP Team. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis. 2007;44(10):1361-1367
45. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120(5). Available at: www.pediatrics.org/cgi/content/full/120/5/e1134
46. Zhang F, Haberer J, Zhao Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr. 2007;46(5):594-598
47. Rajasekaran S, Jeyaseelan L, Ravichandran N, Gomathi C, Thara F, Chandrasekar C. Efficacy of antiretroviral therapy program in children in India: prognostic factors and survival analysis. J Trop Pediatr. 2009;55(4):225-232
48. Kline M, Rugina S, Ilie M, et al. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy. Pediatrics. 2007;119(5). Available at: www.pediatrics.org/cgi/content/full/119/5/e1116
49. Aurpibul L, Puthanakit T, Taecharoenkul S, Sirisanthana V. Impact of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) on weight and height of antiretroviral-naive HIV-infected children [abstract CDB103]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa. Available at: www.ias2009.org/abstract.aspx?elementId=200721497. Accessed December 15, 2010
50. Lapphra K, Vanprapar N, Chearskul S, et al. Efficacy and tolerability of nevirapine-versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis. 2008;12(6):e33-e38
51. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44(4):599-604 (Pubitemid 46233267)
52. Romanelli R, Pinto J, Melo L, Vasconcelos M, Pereira RM. Effectiveness of dual and triple antiretroviral therapy in the treatment of HIV-infected children [in Portuguese]. J Pediatr (Rio J). 2006;82(4):260-265
53. Martins Oliveira Diniz L, Marie Martins Maia M, Silveira Camargos L, Custódio Amaral L, Goulart E, Andrade Pinto J. Long-term effects of HAART on weight and height among Brazilian children infected with HIV [abstract CDB105]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa. Available at: www.ias2009.org/abstract.aspx?elementId=200722217. Accessed December 15, 2010
54. + cell percentage among Brazilian children infected with HIV [abstract MOPEB087]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa. Available at: www.ias2009.org/abstract.aspx?elementId=200722230. Accessed December 15, 2010
55. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353(22):2325-2334
56. Ghaffari G, Passalacqua D, Caicedo J, Goodenow M, Sleasman J. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Pediatrics. 2004; 114(5). Available at: www.pediatrics.org/cgi/content/full/114/5/e604
57. King J, Nachman S, Yogev R, et al. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Pediatr Infect Dis J. 2005;24(10):880-885
58. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999;28(5):1109-1118
59. McKinney RJ, Rodman J, Hu C, et al; Pediatric AIDS Clinical Trials Group Protocol P1021 Study Team. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics. 2007;120(2). Available at: www.pediatrics.org/cgi/content/full/120/ 2/e416
60. Melvin A, Lewis P, Mohan K, Naugler W, Frenkel L. Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children. Arch Pediatr Adolesc Med. 2002;156(6):568-573
61. Patel K, Hernan M, Williams P, et al; Pediatric AIDS Clinical Trials Group 219/219C Study Team. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46(4):507-515
62. Rosenblatt H, Stanley K, Song L, et al. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. J Infect Dis. 2005;192(3):445-455
63. Soh C, Oleske J, Brady M, et al; Pediatric AIDS Clinical Trials Group. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362(9401):2045-2051
64. Spector S, Hsia K, Yong F, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. J Infect Dis. 2000;182(6):1769-1773
65. Starr S, Fletcher C, Spector S, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999;341(25):1874-1881
66. Watson D, Farley J. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18(8):682-689
67. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial - PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses. 2000;16(12):1113-1121
68. Yogev R, Lee S, Wiznia A, et al; Pediatrics AIDS Clinical Trials Group 338 Study Team. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2002;21(2):119-125
69. Bracher L, Valerius N, Rosenfeldt V, et al. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark. Scand J Infect Dis. 2007;39(9):799-804
70. Teglas J, Quartier P, Treluyer J, Burgard M, Gregoire V, Blanche S. Tolerance of efavirenz in children. AIDS. 2001;15(2):241-243
71. Thuret I, Michel G, Chambost H, et al. Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency. AIDS. 1999;13(1):81-87
72. Wintergerst U, Hoffmann F, Jansson A, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother. 2008;61(6):1336-1339
73. Fraaij P, Verweel G, van Rossum A, et al. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(4):604-608
74. Scherpbier H, Bekker V, Pajkrt D, Jurriaans S, Lange J, Kuijpers T. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics. 2007;119(3). Available at: www.pediatrics.org/cgi/content/full/119/3/e705
75. van Rossum A, Geelen S, Hartwig N, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34(7):1008-1016
76. van Rossum A, Niesters H, Geelen S, et al. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children With HIV-1 infections. J Pediatr. 2000;136(6):780-788
77. Verweel G, van Rossum A, Hartwig N, Wolfs T, Scherpbier H, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002;109(2). Available at: www.pediatrics.org/cgi/content/full/109/ 2/e25
78. Nadal D, Steiner F, Cheseaux J, et al. Longterm responses to treatment including ritonavir or nelfinavir in HIV-1-infected children [published correction appears in Infection. 2000;28(6):402]. Pediatric AIDS Group of Switzerland. Infection. 2000;28(5):287-296
79. Rudin C, Burri M, Shen Y, Rode R, Nadal D. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Pediatr Infect Dis J. 2008;27(5):431-437
80. Judd A, Doerholt K, Tookey P, et al; Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC). Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis. 2007;45(7):918-924
81. Walker A, Doerholt K, Sharland M, Gibb D. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18(14):1915-1924
82. Paediatric European Network for Treatment of AIDS. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002;359(9308):733-740
83. Caudill S, Goldman T, Marconi K. Evaluation of pediatric HIV care provided in Ryan White CARE Act Title IV Women, Infants, Children, and Youth Clinics. AIDS Patient Care STDS. 2003;17(2):65-73
84. Lindsey J, Hughes M, McKinney R, et al. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis. 2000;182(5):1385-1393
85. Resino S, Resino R, Maria Bellón J, et al; Spanish Group of Pediatric HIV Infection. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis. 2006;43(2):243-252
86. Pelton S, Johnson D, Chadwick E, Baldwin Z, Yogev R. A one year experience: T cell responses and viral replication in children with advanced human immunodeficiency virus type 1 disease treated with combination therapy including ritonavir. Pediatr Infect Dis J. 1999;18(7):650-652
87. de Martino M, Tovo P, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000;284(2):190-197
88. Kline M, Matusa R, Copaciu L, Calles N, Kline N, Schwarzwald H. Comprehensive pediatric human immunodeficiency virus care and treatment in Constanta, Romania: implementation of a program of highly active antiretroviral therapy in a resource-poor setting. Pediatr Infect Dis J. 2004;23(8):695-700
89. Doerholt K, Duong T, Tookey P, et al; Collaborative HIV Paediatric Study. Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25(5):420-426
90. Funk M, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS. 1999;13(13):1653-1658
91. Gibb D, Goodall R, Giacomet V, McGee L, Compagnucci A, Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J. 2003;22(1):56-62 (Pubitemid 36091779)
92. United Nations Children's Fund. Information by country and programme. Available at: www.unicef.org/infobycountry/index. html. Accessed April 17, 2010).
93. Adetunji J. Trends in under-5 mortality rates and the HIV/AIDS epidemic. Bull World Health Organ. 2000;78(10):1200-1206
94. Newell M, Brahmbhatt H, Ghys P. Child mortality and HIV infection in Africa: a review. AIDS. 2004;18(suppl 2):S27-S34
95. Violari A, Cotton M, Gibb D, et al; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233-2244
96. Eley B. Antiretroviral therapy during infancy: essential intervention for resourcelimited settings. Expert Rev Anti Infect Ther. 2008;6(5):585-589
97. World Health Organization. Antiretroviral Therapy for HIV in Infants and Children: Towards Universal Access - Recommendations for a Public Health Approach. 2010 revision. Geneva, Switzerland: World Health Organization; 2010. Available at: www.who.int/hiv/pub/paediatric/infants/en/index. html. Accessed July 26, 2010
98. Adjé-Touré C, Hanson D, Talla-Nzussouo N, Borget M, Kouadio L, Tossou O, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire. AIDS Res Hum Retroviruses. 2008;24(7):911-917
99. Biadgilign S, Deribew A, Amberbir A, Deribe K. Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia. BMC Pediatr. 2008;8:53
100. Onankpa B, Airede L, Paul I, Dorcas I. Pattern of pediatric HIV/AIDS: a five-year experience in a tertiary hospital. J Natl Med Assoc. 2008;100(7):821-825
101. Cowburn C, Hatherill M, Eley B, Nuttall J, Hussey G, Reynolds L, et al. Short-term mortality and implementation of antiretroviral treatment for critically ill HIV-infected children in a developing country. Arch Dis Child. 2007;92(3):234-241
102. Eley B, Nuttall J, Davies M, Smith L, Cowburn C, Buys H, et al. Initial experience of a public sector antiretroviral treatment programme for HIV-infected children and their infected parents. S Afr Med J. 2004;94(8):643-646
103. Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS. 2008;22(11):1333-1343
104. van Kooten Niekerk NK, Knies MM, Howard J, Rabie H, Zeier M, van Rensburg A, et al. The first 5 years of the family clinic for HIV at Tygerberg Hospital: family demographics, survival of children and early impact of antiretroviral therapy. J Trop Pediatr. 2006;52(1):3-11
105. Atakouma D, Tsolenyanu E, Gbadoe A, Gbetoglo V, Lawson-Evi K, Agbere A, et al. [Primary results of antiretroviral treatment among HIV/AIDS infected children in Lomé (Togo)]. Arch Pediatr. 2007;14(10):1178-1182
106. Polisset J, Ametonou F, Arrive E, Aho A, Perez F. Correlates of Adherence to Antiretroviral Therapy in HIV-Infected Children in Lomé, Togo, West Africa. AIDS Behav. 2009;13(1):23-32
107. Fallo A, DobrzanskiNisiewicz W, Sordelli N, Cattaneo M, Scott G, López E. Clinical and epidemiologic aspects of human immunodeficiency virus-1-infected children in Buenos Aires, Argentina. Int J Infect Dis. 2002;6(1):9-16
108. Matida L, Marcopito L, Succi R, Marques H, Della Negra M, Grangeiro A, et al. Improving survival among Brazilian children with perinatally-acquired AIDS. Braz J Infect Dis. 2004;8(6):41-423
109. Candiani T, Pinto J, Cardoso C, Carvalho I, Dias A, Carneiro M, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica. 2007;23 Suppl 3:S414-423
110. Samayoa B, Anderson M, Grazioso C, Rivera B, Harrison M, O'Brien W, et al. Experience of a pediatric HIV clinic in Guatemala City. Rev Panam Salud Publica. 2009;25(1):51-55
111. Evans-Gilbert T, Pierre R, Steel-Duncan J, Rodriguez B, Whorms S, Hambleton I, et al. Antiretroviral drug therapy in HIV-infected Jamaican children. West Indian Med J. 2004;53(5):322-326
112. Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS. 2007;21(3):351-359
113. Kumarasamy N, Venkatesh K, Devaleenol B, Poongulali S, Mothi S, Solomon S. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr. 2009;55(3):155-159
114. Lodha R, Upadhyay A, Kabra SK. Antiretroviral therapy in HIV-1 infected children. Indian Pediatr. 2005;42(8):789-796
115. Natu S, Daga S. Antiretroviral therapy in children: Indian experience. Indian Pediatr. 2007;44(5):339-343
116. Pensi T. Fixed Dose Combination of Lamivudine, Stavudine and Nevirapine in the Treatment of Pediatric HIV infection: A Preliminary Report. Indian Pediatr. 2007;44(7):519-521
117. Ferris M, Burau K, Schweitzer A, Mihale S, Murray N, Preda A, et al. The influence of disclosure of HIV diagnosis on time to disease progression in a cohort of Romanian children and teens. AIDS Care. 2007;19(9):1088-1094 (Pubitemid 350223185)
118. Chearskul P, Chokephaibulkit K, Chearskul S, Phongsamart W, Plipat N, Lapphra K, et al. Effect of antiretroviral therapy in human immunodeficiency virus-infected children. J Med Assoc Thai. 2005;88 Suppl 8:S221-S231
119. Koekkoek S, Eggermont L, De Sonneville L, Jupimai T, Wicharuk S, Apateerapong W, et al. Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease. J Neurol. 2006;253(12):1615-1624
120. Plipat N, Cressey T, Vanprapar N, Chokephaibulkit K. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2007;26(1):86-88
121. Arrivé E, Kyabayinze DJ, Marquis B, Tumwesigye N, Kieffer MP, Azondekon A, et al. Cohort profile: the paediatric antiretroviral treatment programmes in lowerincome countries (KIDS-ART-LINC) collaboration. Int J Epidemiol. 2008;37(3):474-480
122. The KIDS-ART-LINC Collaboration. Low Risk of Death, but Substantial Program Attrition, in Pediatric HIV Treatment Cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2008;49(5):523-531
123. Saez-Llorens X, Violari A, Ndiweni D, Yogev R, Cashat M, Wiznia A, et al. Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. Pediatrics. 2008;121(4):e827-e835
124. Weidle P, Abrams E, Gvetadze R, Rivadeneira E, Kline M. A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings. Pediatr Infect Dis J. 2006;25(1):59-64
125. Hazra R, Stoszek SK, Freimanis Hance L, Pinto J, Marques H, Peixoto M, et al. Cohort Profile: NICHD International Site Development Initiative (NISDI): a prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countries. Int J Epidemiol. 2009;38(5):1207-1214
126. Hainaut M, Peltier C, Gérard M, Marissens D, Zissis G, Levy J. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr. 2000;159(10):778-782
127. Aboulker J, Babiker A, Chaix M, Compagnucci A, Darbyshire J, Debré M, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS. 2004;18(2):237-245
128. Faye A, Bertone C, Teglas J, Chaix M, Douard D, Firtion G, et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J. 2002;21(6):518-525
129. Wintergerst U, Hoffmann F, Sölder B, Notheis G, Petropoulou T, Eberle J, et al. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 1998;17(6):495-499
130. Canani R, Spagnuolo M, Cirillo P, Guarino A. Decreased needs for hospital
131. Chiappini E, Galli L, Tovo P, Gabiano C, Lisi C, Gattinara G, et al. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS. 2007;21(12):1607-1615
132. Viganò A, Schneider L, Giacomet V, Bianchi R, Cicero M, Soster F, et al. Efficacy and tolerability of multiple drug therapy in HIV-infected children. J Infect. 2005;50(5):404-411
133. Cohen Stuart JW, Slieker WA, Rijkers GT, Noest A, Boucher CA, Suur MH, et al. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. AIDS. 1998;12(16):2155-2159
134. Larrú B, Resino S, Bellón J, de José M, Fortuny C, Navarro M, et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. J Antimicrob Chemother. 2007
135. Resino S, Bellón JM, Ramos JT, Resino R, Gurbindo MD, Mellado MJ, et al. Impact of highly active antiretroviral therapy on CD4+ T cells and viral load of children with AIDS: a population-based study. AIDS Res Hum Retroviruses. 2004;20(9):927-931
136. Sánchez J, Ramos Amador J, Fernández de Miguel S, González Tomée M, Rojo Conejo P, Ferrnado Vivas P, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22(10):863-867
137. Guillén Martín S, Ramos Amador J, Resino García R, Bellón Cano J. [Epidemiological trends in new diagnoses of HIV-1 infection in children]. An Pediatr (Barc). 2005;63(3):199-202
138. Steiner F, Kind C, Aebi C, Wyler-Lazarevitch C, Cheseaux J, Rudin C, et al. Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors. Eur J Pediatr. 2001;160(10):611-616
139. Newell M, Patel D, Goetghebuer T, Thorne C. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis. 2006;193(7):954-962
140. Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS. 2009;23(5):597-604
141. Abrams E, Weedon J, Bertolli J, Bornschlegel K, Cervia J, Mendez H, et al. Aging cohort of perinatally human immunodeficiency virus-infected children in New York City. New York City Pediatric Surveillance of Disease Consortium. Pediatr Infect Dis J. 2001;20(5):511-517
142. Benjamin DJ, Miller W, Benjamin D, Ryder R, Weber D, Walter E, et al. A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. AIDS. 2003;17(16):2331-2336
143. Berrien V, Salazar J, Reynolds E, McKay K. Adherence to antiretroviral therapy in HIV-infected pediatric patients improves with home-based intensive nursing intervention. AIDS Patient Care STDS. 2004;18(6):355-363
144. Blazevic V, Jankelevich S, Steinberg S, Jacobsen F, Yarchoan R, Shearer G. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses. Clin Diagn Lab Immunol. 2001;8(5):943-948
145. Borkowsky W, Stanley K, Douglas S, Lee S, Wiznia A, Pelton S, et al. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis. 2000;182(1):96-103
146. Brady M, Oleske J, Williams P, Elgie C, Mofenson L, Dankner W, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53(1):86-94
147. Brogly S, Williams P, Seage Gr, Oleske J, Van Dyke R, McIntosh K. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA. 2005;293(18):2213-2220
148. Brundage R, Yong F, Fenton T, Spector S, Starr S, Fletcher C. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother. 2004;48(3):979-984
149. Buchacz K, Cervia J, Lindsey J, Hughes M, Seage Gr, Dankner W, et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics. 2001;108(4):E72
150. Chadwick E, Rodman J, Britto P, Powell C, Palumbo P, Luzuriaga K, et al. Ritonavirbased highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J. 2005;24(9):793-800
151. Chadwick E, Capparelli E, Yogev R, Pinto J, Robbins B, Rodman J, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS. 2008;22(2):249-255
152. Chougnet C, Jankelevich S, Fowke K, Liewehr D, Steinberg S, Mueller B, et al. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. J Infect Dis. 2001;184(2):201-205
153. Church JA, Cunningham C, Hughes M, Palumbo P, Mofenson LM, Delora P, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2002;21(7):653-659
154. Essajee S, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS. 1999;13(18):2523-2532
155. Flynn P, Rudy B, Douglas S, Lathey J, Spector S, Martinez J, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004;190(2):271-279 (Pubitemid 38951966)
156. Flynn P, Rudy B, Lindsey J, Douglas S, Lathey J, Spector S, et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses. 2007;23(10):1208-1214
157. Glikman D, Walsh L, Valkenburg J, Mangat P, Marcinak J. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications. Pediatrics. 2007;119(5):e1142-e1148
158. Gona P, Van Dyke R, Williams P, Dankner W, Chernoff M, Nachman S, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296(3):292-300
159. Jankelevich S, Mueller B, Mackall C, Smith S, Zwerski S, Wood L, et al. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J Infect Dis. 2001;183(7):1116-1120
160. Johnston A, Valentine M, Ottinger J, Baydo R, Gryszowka V, Vavro C, et al. Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. Pediatr Infect Dis J. 2001;20(10):941-946 (Pubitemid 32952670)
161. King J, Acosta E, Yogev R, Wiznia A, Kraimer J, Graham B, et al. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 2009;28(2):159-161
162. Kline M, Fletcher C, Harris A, Evans K, Brundage R, Remmel R, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr. 1998;132(3 Pt 1):543-546
163. Lee G, Gortmaker S, McIntosh K, Hughes M, Oleske J. Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics. 2006;117(2):273-283
164. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 1997;336(19):1343-1349
165. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan J. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350(24):2471-2480
166. McConnell MS, Byers RH, Frederick T, Peters VB, Dominguez KL, Sukalac T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr. 2005;38(4):488-494
167. Melvin A, Mohan K, Arcuino L, Edelstein R, Frenkel L. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J. 1997;16(10):968-974 (Pubitemid 27452315)
168. Mueller B, Nelson RJ, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg S, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics. 1998;101(3 Pt 1):335-343 (Pubitemid 28136403)
169. Mueller B, Sleasman J, Nelson RJ, Smith S, Deutsch P, Ju W, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics. 1998;102(1 Pt 1):101-109
170. Nachman S, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000;283(4):492-498
171. Palumbo P, Raskino C, Fiscus S, Pahwa S, Schutzbank T, Spector S, et al. Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children. J Infect Dis. 1999;179(3):576-583
172. Patel K, Hernán M, Williams P, Seeger J, McIntosh K, Dyke R, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008;46(11):1751-1760
173. Pelton S, Stanley K, Yogev R, Fletcher C, McIntosh K, Wiznia A, et al. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children. Clin Infect Dis. 2005;40(8):1181-1187
174. Polis M, Sidorov I, Yoder C, Jankelevich S, Metcalf J, Mueller B, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet. 2001;358(9295):1760-1765
175. Reddington C, Cohen J, Baldillo A, Toye M, Smith D, Kneut C, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2000;19(12):1148-1153
176. Robbins B, Capparelli E, Chadwick E, Yogev R, Serchuck L, Worrell C, et al. Pharmacokinetics of High-Dose Lopinavir/Ritonavir with and without Saquinavir or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors-Study PACTG P1038. Antimicrob Agents Chemother. 2008
177. Rutstein R, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS. 1997;11(12):F107-F111
178. Storm D, Boland M, Gortmaker S, He Y, Skurnick J, Howland L, et al. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics. 2005;115(2):e173-e182
179. Van Dyke R, Lee S, Johnson G, Wiznia A, Mohan K, Stanley K, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109(4):e61
180. Viani R, Araneta M, Deville J, Spector S. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39(5):725-731
181. Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J. 2007;26(9):799-805
182. Ayaya S, Nyandiko W, Vreeman R, Wafula S, Rotch J. Progression of HIV Infection in children attending the academic model providing access to healthcare (AMPATH) clinics in Western Kenya [abstract CDB006]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
183. McGrath C, Chung M, Richardson B, et al. Growth in HIV-1-infected children in Kenya following the initiation of HAART [abstract WEPEB191]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
184. Owiso G, Odawo P, Njoroge A, Meresey J, Muriithi C. Partnering with community health workers to improve pediatrics HIV testing and ART adherence [abstract WEPEB279]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
185. Wamalwa D, Obimbo E, Farquhar C, et al. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya [abstract MOPEB086]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
186. Ndirangu J, Bland R, Newell ML. Weight and weight gain in HIV-infected children receiving antiretroviral therapy in rural KwaZulu-Natal [abstract WEPEB188]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
187. Braun M, Kabue M, Chirwa M, et al. Challenges in pediatric HIV referral: evidence for PMTCT, infant diagnosis, and pediatric HIV clinic integration in Lilongwe, Malawi [abstract WEPED218]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
188. Dow A, Dube Q, Chirambo CM, Moore M, Heyderman R, Van Rie A. Community based early infant testing and treatment: experience from Blantyre, Malawi [abstract CDB098]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
189. Kabue MM, Buck WC, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children [abstract WEPED175]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
190. Kabue MM, Braun M, Aetker L, et al. ART initiation and increased survival of infants traced from PMTCT to pediatric HIV care: highlighting the need for program coordination in Lilongwe, Malawi [abstract WEPDD103]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
191. Chouraya C, Mahdi MA, Kieffer MP, Lukhele B. Implementing early antiretroviral treatment for infants in Swaziland [abstract CDB078]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
192. Colvin CJ, Knight L, Van Cutsem G, et al. Paediatric outcomes after five years on ART in Khayelitsha Township, South Africa [abstract CDB109]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
193. Coovadia A, Abrams E, Strehlau R, et al. Randomized clinical trial of switching to nevirapine-based therapy for infected children exposed to nevirapine prophylaxis [abstract MOAB103]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
194. Fatti G, Bock P, Grimwood A, Wampold S, Eley B. Antiretroviral therapy outcomes in rural and urban children attending public health facilities in South Africa [abstract MOPEB077]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
195. Fenner L, Keiser O, Brinkhof M, et al. Mortality, loss to follow-up and transfer-out in paediatric ART programmes in Southern Africa [abstract WEPEB276]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
196. Kaplan R, Bekker LG, Zwane E, Campbell E, Orrell C, Wood R. Long term programmatic outcomes for adults and children at a primary health care antiretroviral clinic in South Africa [abstract MOAD105]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
197. Kekitiinwa A, Maganda A, Tumbu P, Asiimwe Rwego A, Kiboneka E. Mortality rate among malnourished HIV-infected children in Kampala, Uganda: implications for time to initiate HAART [abstract MOPEB046]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
198. Augustinova D, Ban B, Kong C, et al. Health care of children diagnosed HIV positive before 18 months in Chea Chumneas Hospital, Takhmao, Cambodia [abstract CDC026]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
199. Isaakidis P, Raguenaud ME, Te V, et al. High survival and treatment success sustained after up to three years of ART for children in Cambodia [abstract MOAB102]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
200. Sophan S, Vibol U, Chanatheany H, et al. Lopinavir/ritonavir-based second line antiretroviral treatment in children at National Pediatric Hospital, Phnom Penh, Cambodia [abstract CDD020]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
201. Gnana Durai Pandian AG, Kandaswamy R, Nadol P, Chandrasekar S. Clinical and immunological response to highly active antiretroviral therapy (HAART) in paediatric patients-a retrospective cohort study at Government Hospital of Thoracic Medicine, India [abstract CDB102]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
202. McConnell M, Yuktanont P, Siangphoe U, et al. Survival rates following expansion of the national pediatric antiretroviral treatment program, Thailand, 2000-2005 [abstract MOAB101]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
203. Rezende R, Maia M, Diniz L, Camargos L, Amaral L, Pinto J. Impact of HAART in growth parameters of HIV-infected children in Minas Gerais, Brazil [abstract CDB104]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
204. Carter RJ, Katyal M, Toro P, Abrams EJ. Immunologic response and survival of infants initiating antiretroviral treatment (ART) at less than one year of age compared to older children enrolled at MTCTPlus Initiative sites in 8 African countries and Thailand [abstract MOPEB048]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
205. Hansudewechakul R, Naiwatanakul T, Faikratok W, et al. Clinical outcomes in a community-based pediatric HIV care network in Chiang Rai, Thailand, 2002-2008 [MOPEB084]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
206. Davies MA, Wood R, Van Cutsem G, et al. Virologic failure and second-line antiretroviral therapy (ART) in children in South Africa: the international epidemiologic databases to evaluate AIDS (IeDEA) Southern Africa collaboration [abstract MOAB104]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
207. Palumbo P, Violari A, Lindsey J, et al. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial [abstract LBPEB12]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
208. Bognon T, Azondekon A, Homawoo E, et al. Networking between medical centers and ART pediatric site: what are the benefits for children? [abstract WEPDD105]. Presented at: 5th International AIDS Society conference on HIV Pathogenesis and Treatment; July 19-22, 2009; Cape Town, South Africa
209. Venkatesh K, De Bruyn G, Marinda E, et al. Morbidity and Mortality among Infants Born to HIV-infected Women in South Africa: Implications for Child Health in Resource-limited Settings [paper 841]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19 2010; San Francisco, CA
210. Achan J, Ruel T, Li P, et al. Incidence of Early Virological Failure and the Evolution of Antiretroviral Drug Resistance Mutations in Ugandan Children [paper 849]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19 2010; San Francisco, CA
211. Becquet R, et al. Survival of Children HIV-infected Perinatally or through Breastfeeding: A Pooled Analysis of Individual Data from Sub-Saharan Africa [paper 840]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19 2010; San Francisco, CA
212. Pandian PG, Chandran P, Kandasamy C. Persistence of Stunting after HAART in HIV-infected Children in South India [paper 847]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19 2010; San Francisco, CA
213. + Children: Comparison of the Pre-PCP Prophylaxis, Pre-ART, and ART Era [paper 856]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19 2010; San Francisco, CA
214. Palladino C, Briz V, Negre-Policarpo S, et al. Long-term (>180 Weeks) Efficacy and Safety of Fosamprenavir in HIV-infected Pediatric Patients in Clinical Practice [paper 876]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19 2010; San Francisco, CA
215. Nachman S, Samson P, Acosta E, et al. Pharmacokinetic, Safety, and Efficacy Data on Cohort IIA; Youth Aged 6 to 11 Years from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir in HIV-1-infected Youth [paper 873]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19 2010; San Francisco, CA